Risk factor
Very high price volatility
Profitability factor
Greatly overvalued vs peers
About
Endurance RP Limited functions as an investment holding company, concentrating its investments within the healthcare and life sciences sectors across the People's Republic of China, Europe, Hong Kong, and Taiwan. The firm organizes its activities into two primary divisions: Biopharma and Corporate Investment. The Biopharma segment is responsible for the research, development, production, promotion, and distribution of pharmaceutical products aimed at addressing and managing urological disorders. This division also innovates artificial intelligence systems to precisely track the pace of aging, examining it at molecular, cellular, tissue, organ, systemic, physiological, and psychological levels. Through its Corporate Investment division, the company strategically invests in both publicly traded and privately held corporate entities. Additionally, it extends its services to include management consulting and corporate financial advice. Incorporated in 1991 and headquartered in Central, Hong Kong, Endurance RP Limited adopted its current name in June 2021, having previously operated as Regent Pacific Group Limited.
Company Valuation
Based on key historical and expected multiples, the stock is greatly overvalued relative to its peers.